Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~For Exposed vaccinated cohort:~* Written informed consent, and assent in case of minors, obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject.~* Aged between, and including, 15 and 25 years of age.~* Residing within the US or Canada.~* Subjects who received at least one dose of CERVARIX.~* Gestational age at inclusion should be 19 completed weeks (i.e. 133 days of gestation) or less.~* Last menstrual period between 30 days before and 90 days after any dose of CERVARIX with a maximum of 20% of subjects with last menstrual period between 46 and 90 days after any dose of CERVARIX.~* Subjects who the Investigator believes can and will comply with the requirements of the protocol (e.g. available for phone interviews). Or subjects who the Investigator believes that parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol.~For Non-exposed vaccinated cohort:~* Written informed consent, and assent in case of minors, obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject.~* Aged between, and including, 15 and 25 years of age.~* Residing within the US or Canada.~* Subjects who received at least one dose of CERVARIX or at least one dose of GARDASIL.~* Gestational age at inclusion should be 19 completed weeks (i.e. 133 days of gestation) or less.~* Last menstrual period between 120 days and 18 months after the last dose of CERVARIX/ GARDASIL.~* Subjects who the Investigator believes can and will comply with the requirements of the protocol (e.g. available for phone interviews). Or subjects who the Investigator believes that parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol.~Exclusion Criteria:~For Exposed vaccinated cohort:~* Last menstrual period between 30 days before and 90 days after any GARDASIL dose.~* Ongoing pregnancy with foetus known to be non-viable.~* Ongoing pregnancy with pre-enrolment knowledge by prenatal diagnosis of a major structural defect.~* Use of any investigational or non-registered product (drug or vaccine) during the study period.~For Non-exposed vaccinated cohort:~* Ongoing pregnancy with foetus known to be non-viable.~* Ongoing pregnancy with pre-enrolment knowledge by prenatal diagnosis of a major structural defect.~* Use of any investigational or non-registered product (drug or vaccine) during the study period.

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Exposed vaccinated cohort (Type: None): Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.
- Non-exposed vaccinated cohort (Type: None): Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues